EmboCube™ and Torpedo™ Safely and Effectively Help Physicians Control Bleeding and Hemorrhaging in the Peripheral Vasculature
SOUTH JORDAN, Utah – February 3, 2020 – Merit Medical Systems, Inc. (NASDAQ:MMSI) announces that both its EmboCube (syringe-loaded embolization gelatin foam) and Torpedo (uniform, pre-shaped gelatin foam loaded into a cartridge with optional blunt stylet) devices are now FDA indicated for the embolization of blood vessels to occlude blood flow, which helps control bleeding and hemorrhaging in the peripheral vasculature.
EmboCube is the only gelatin foam that is delivered pre-cut and pre-loaded into a syringe for efficiency and ease of use. Torpedo provides physicians a uniformly pre-shaped gelatin foam loaded into a cartridge with an optional blunt stylet, removing the need for manual foam shaping, providing fast and easy attachment to the catheter for delivery. EmboCube and Torpedo are made of porcine gelatin and have no ferrous composition, making it safe for use in patients undergoing magnetic resonance imaging (MRI).
“Our embolization technologies, including the EmboCube and Torpedo devices, are vital parts of Merit’s core business, which delivers physicians quality products that improve the standard of care and confer tangible patient benefits,” commented Fred Lampropoulos, Chairman and Chief Executive Officer, Merit Medical. “The new indication for EmboCube and Torpedo accurately conveys its safety and efficacy for blood flow occlusion in adult patients, and the Merit team is excited to commercialize this excellent product accordingly.”
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 300 individuals. Merit employs approximately 6,400 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; Aliso Viejo, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; Reading, United Kingdom; Johannesburg, South Africa; and Singapore.
Pascale Communications, LLC